Inspire Advisors LLC Makes New Investment in Bausch Health Cos Inc. $BHC

Inspire Advisors LLC acquired a new stake in shares of Bausch Health Cos Inc. (NYSE:BHCFree Report) in the second quarter, HoldingsChannel reports. The fund acquired 71,745 shares of the company’s stock, valued at approximately $478,000.

Several other large investors also recently made changes to their positions in BHC. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Bausch Health Cos by 10.9% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 64,310 shares of the company’s stock worth $428,000 after buying an additional 6,340 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Bausch Health Cos by 73.4% in the 2nd quarter. Cetera Investment Advisers now owns 19,849 shares of the company’s stock worth $132,000 after purchasing an additional 8,402 shares in the last quarter. Creative Planning increased its holdings in shares of Bausch Health Cos by 16.9% in the second quarter. Creative Planning now owns 50,493 shares of the company’s stock valued at $336,000 after buying an additional 7,304 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Bausch Health Cos by 114.4% in the 2nd quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after acquiring an additional 3,282,684 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after buying an additional 84,892 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on BHC shares. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.00.

View Our Latest Stock Report on Bausch Health Cos

Bausch Health Cos Stock Down 2.2%

BHC opened at $6.05 on Thursday. Bausch Health Cos Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $8.69. The company has a market capitalization of $2.24 billion, a P/E ratio of 23.25 and a beta of 0.47. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The firm’s fifty day moving average price is $6.50 and its two-hundred day moving average price is $6.24.

Bausch Health Cos Profile

(Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Further Reading

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Cos Inc. (NYSE:BHCFree Report).

Institutional Ownership by Quarter for Bausch Health Cos (NYSE:BHC)

Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.